[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endovascular-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endovascular-treatment":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,44,70,94,126,153,174,198,226,248,271,295,321],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100620466","phase-3-intra-arterial-tenecteplase-for-acute-medium-vessel-occlusion-stroke-100620466",false,"NCT07357987","Intra-arterial Tenecteplase for Acute Medium Vessel Occlusion Stroke","Intra-arterial Tenecteplase for Acute Medium Vessel Occlusion Stroke: the ANGEL-MeVO-TNK Randomized Clinical Trial","ANGEL-MeVO-TNK","Inclusion Criteria:\n\nClinical Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Pre-stroke mRS 0-1;\n3. Within 24 h from symptom onset;\n4. Baseline National Institutes of Health Stroke Scale (NIHSS) score \\>5 or baseline NIHSS 3-5 with disabling deficit (e.g., loss of hand function, aphasia, hemianopia);\n5. Informed consent obtained from patients or their legal representatives.\n\nImaging Inclusion Criteria:\n\n1. Baseline CTA\u002FMRA\u002FDSA diagnosed isolated MeVO, referring to the M2\u002FM3 segment of the MCA, the A1\u002FA2\u002FA3 segment of the ACA, the P1\u002FP2\u002FP3 segment of the PCA;\n2. NCCT or MRI DWI imaging showing that the territory of the ischemic infarct volume is less than 50% of the estimated territory supplied by the occluded artery.\n\nExclusion Criteria:\n\n1. Acute intracranial hemorrhage;\n2. ASPECT ≤5;\n3. MeVO secondary to spontaneous fragmentation and distal migration of thrombus from an acute large vessel occlusion, or occurring after intravenous thrombolysis (IVT), intra-arterial thrombolysis, or endovascular thrombectomy;\n4. Contraindication to TNK;\n5. Known severe allergy to contrast agents (excluding mild rash-type allergic reactions);\n6. Use of heparin or novel oral anticoagulants within the previous 48 hours with an INR ≥ 1.7;\n7. A history of major bleeding within the past 6 months or the presence of conditions such as active gastrointestinal ulcer, aortic dissection, platelet count \\\u003C 100 × 10⁹\u002FL, etc.;\n8. Radiologically confirmed vascular malformations, arterial dissection, intracranial aneurysm (diameter≥3 mm), tumors (except small meningiomas), cerebral vasculitis, cerebral amyloid angiopathy, or other major non-ischemic intracranial diseases (e.g., multiple sclerosis);\n9. Acute renal failure, current dialysis, or estimated glomerular filtration rate (eGFR)\\\u003C30ml\u002Fmin\u002F1.72m2, and\u002For serum creatinine\\>220mmol\u002FL (2.5mg\u002Fdl);\n10. History of severe liver disease, or aspartate aminotransferase (AST) and\u002For alanine aminotransferase (ALT) and\u002For glutamyl transferase (GGT) ≥3×upper limit of normal value (ULN) and\u002For total bilirubin (TBIL) ≥2×ULN;\n11. Severe non-cardiovascular comorbidity with an expected life expectancy of less than 3 months (e.g., malignant tumors);\n12. Known pregnancy or breastfeeding, or a positive pregnancy test prior to randomization;\n13. Current participation in another drug or device clinical trial;\n14. Any other condition deemed by the investigator to make the patient unsuitable for participation in the study or to pose a significant risk to the patient (e.g., inability to understand and\u002For comply with study procedures and\u002For follow-up due to psychiatric illness, cognitive impairment, or emotional disorders).","ALL","18 Years",{"count":20,"type":21},488,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The ANGEL-MeVO-TNK is a multicentered, prospective, randomized, open label, blinded endpoint (PROBE) phase III trial. A total of 488 AIS patients (age ≥18 years) with acute MeVO-AIS (occlusion of the M2\u002FM3, the A1\u002FA2\u002FA3, the P1\u002FP2\u002FP3, and with baseline NIHSS score \\>5 or disabling stroke with NIHSS score 3-5 \\[such as neurological deficits in motor strength, language, vision, etc\\]), will be enrolled. Patients fulfilling all the inclusion criteria and none of the exclusion criteria will be randomized 1:1 into the IA TNK group or the control group after offering informed content.\n\n* The IA TNK group：1) If the patient has not received IVT, IA TNK will be administered as a slow, continuous infusion for super-selective contact thrombolysis in a stepwise manner: an initial dose of 0.0625 mg\u002Fkg with a duration of 15 minutes. A repeat angiographic assessment will then be performed; if recanalization is not achieved, an additional dose of 0.0625 mg\u002Fkg will be administered over a further 15 minutes (maximum dose 12.5 mg) .\n\n  2\\) If the patient has received IVT, intra-arterial TNK will be administered as a slow infusion for super-selective contact thrombolysis at a dose of 0.0625 mg\u002Fkg (maximum dose 6.25 mg) with a duration of 15 minutes.\n* The control group will be given standard medical management.\n\nThe study consists of four visits including the day of randomization, 48±12 hours after randomization, and 90±7 days after randomization. Demographic information, symptoms and signs, laboratory test, neuro-imaging assessment neurological function rating scale will be recorded during the program.\n\nThe primary outcome is the modified Rankin Scale (mRS) score of 0 to 1 at 90±7 days after onset. The primary safety outcome is the incidence of sICH within 48±12 hours after randomization (ECASS III).",[27,28,29,30],"Ischemic Stroke","Medium Vessel Occlusion","Tenecteplase","Endovascular Treatment","RECRUITING","2026-04-26",{"date":34,"type":35},"2026-04-30","ACTUAL",{"date":37,"type":35},"2026-01-22",{"date":39,"type":21},"2027-12-31",{"name":41,"class":42},"Beijing Tiantan Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":43},"100635807","randomized-clinical-trial-of-endovascular-treatment-for-progressive-stroke-with-vertebrobasilar-artery-occlusion-100635807","NCT07557485","Randomized Clinical Trial of Endovascular Treatment for Progressive Stroke With Vertebrobasilar Artery Occlusion","Safety and Efficacy of Endovascular Treatment for Progressive Stroke Due to Vertebrobasilar Artery Occlusion: A Multicenter, Prospective, Open-Label Randomized Controlled Trial With Blinded Endpoint Assessment","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Acute ischemic stroke, with a National Institutes of Health Stroke Scale (NIHSS) score of \\\u003C10 at initial symptom onset, and no prior endovascular treatment.\n3. Stroke progression occurring from 24 hours to 14 days after initial symptom onset, defined as an NIHSS score of ≥10 with an increase of ≥4 points from baseline.\n4. Acute basilar artery occlusion or dominant vertebral artery occlusion with contralateral occlusion or hypoplasia, confirmed by CTA, MRA or DSA.\n5. Posterior circulation Alberta Stroke Program Early CT Score (pc-ASPECTS) of ≥6 and Pons-Midbrain Index (PMI) of ≤3 on CT or diffusion-weighted imaging (DWI).\n6. Randomization within 24 hours of stroke progression.\n7. Pre-stroke mRS score of 0-2.\n8. Provision of signed informed consent by the patient or their legal representative.\n\nExclusion Criteria:\n\n1. Any sign of intracranial hemorrhage (except microbleeds) on baseline brain imaging.\n2. Imaging confirms the progression of symptoms caused by intracranial hemorrhage, brain edema, or other clear causes.\n3. Extensive cerebellar infarction with significant mass effect or bilateral thalamic infarction on baseline neuroimaging.\n4. Presence of untreated intracranial aneurysm, intracranial tumor (except small meningioma and aneurysms \\\u003C3 mm in diameter), or intracranial arteriovenous malformation.\n5. Known or highly suspected chronic responsible artery occlusion.\n6. Presence of severe stenosis in the extracranial or intracranial segment of the responsible artery, arterial dissection, or excessive vascular tortuosity that may prevent successful delivery or navigation of endovascular devices.\n7. Known contraindication to contrast medium (except mild rash).\n8. Refractory hypertension not controlled by medication, defined as systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg.\n9. Known pregnancy or lactation, or a positive pregnancy test prior to randomization.\n10. Known dementia or psychiatric disease precluding completion of neurological assessment and follow-up.\n11. Life expectancy \\\u003C1 year, including patients with malignancy or advanced cardiopulmonary disease.\n12. Current participation in any other clinical trial of drugs or medical devices, or anticipated participation in another such trial within 3 months after enrollment.\n13. Acute ischemic stroke within 48 hours after cardiovascular or cerebrovascular interventional treatment or major surgery; patients presenting \\>48 hours after such procedures were eligible.\n14. Recent (within 1 month) gastrointestinal or genitourinary bleeding, acute myocardial infarction, or traumatic brain injury.\n15. Multivessel severe stenosis or occlusion confirmed by CTA, MRA, or DSA.\n16. Known or suspected central nervous system vasculitis.\n17. Known hereditary or acquired bleeding diathesis, coagulation factor deficiency, current use of oral anticoagulants with an INR \\>1.5, or active bleeding.\n18. Blood glucose \\\u003C2.8 or \\>22.2 mmol\u002FL; platelet count \\\u003C100 × 10⁹\u002FL; estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002F1.73 m² or serum creatinine ≥177 μmol\u002FL (2.0 mg\u002FdL).\n19. Any other condition deemed by the site investigator to make the patient unsuitable for participation.",{"count":52,"type":21},240,[54],"NA","This multicenter, prospective, open-label randomized controlled trial with blinded assessment was designed to assess the efficacy and safety of endovascular treatment for progressive stroke due to vertebrobasilar artery occlusion.",[57,30],"Vertebrobasilar Artery Occlusion",[59,57,30],"Acute Ischemic Stroke","NOT_YET_RECRUITING","2026-04-23",{"date":63,"type":35},"2026-04-29",{"date":65,"type":21},"2026-06-01",{"date":67,"type":21},"2029-12-31",{"name":69,"class":42},"Feng Gao",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":43},"100634303","phase-3-intra-arterial-tirofiban-after-complete-recanalization-for-acute-intracranial-large-vessel-occlusion-100634303","NCT07537933","Intra-Arterial Tirofiban After Complete Recanalization for Acute Intracranial Large-Vessel Occlusion","Efficacy and Safety of Immediate Intra-Arterial Tirofiban After Mechanical Thrombectomy Recanalization in Acute Intracranial Large-Vessel Occlusion","IA-Tirofiban","Inclusion Criteria:\n\nAge ≥18 years; Last known well to arterial puncture within 0 to 24 hours; Preoperative imaging confirms anterior circulation large-vessel occlusion, including intracranial internal carotid artery occlusion or middle cerebral artery M1 or dominant M2 occlusion; Baseline National Institutes of Health Stroke Scale (NIHSS) score 6 to 25; Baseline Alberta Stroke Program Early CT Score (ASPECTS) ≥6 on CT or DWI; Pre-stroke modified Rankin Scale (mRS) score ≤1; eTICI 2c to 3 complete recanalization achieved after mechanical thrombectomy, or spontaneous recanalization to eTICI 2c to 3 confirmed intraoperatively without further thrombectomy; Embolic occlusion with no residual fixed stenosis in the target vessel after thrombectomy; Written informed consent provided by the participant or legally authorized representative.\n\nExclusion Criteria:\n\nPregnancy or breastfeeding; Active bleeding within the previous month or known severe bleeding tendency; Major underlying disease with life expectancy \\\u003C6 months, or inability in the investigator's judgment to complete follow-up; Participation in another interventional clinical trial; Use of oral anticoagulants within 48 hours before symptom onset with INR \\>1.7, or recent use of direct oral anticoagulants not meeting institutional cessation or testing requirements; Platelet count \\\u003C50 × 10\\^9\u002FL; Blood glucose \\\u003C2.8 mmol\u002FL or \\>22.2 mmol\u002FL that cannot be corrected promptly Severe renal insufficiency, defined as eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m² or serum creatinine \\>2.5 mg\u002FdL; Uncontrolled blood pressure, defined as systolic blood pressure \\>185 mmHg or diastolic blood pressure \\>110 mmHg despite treatment; Imaging evidence of intracranial hemorrhage, or presence of an intracranial aneurysm, arteriovenous malformation, brain tumor, or other lesion associated with high bleeding risk; Bilateral acute cerebral infarction or multiple intracranial arterial occlusions Intraoperative vessel rupture, dissection, contrast extravasation, or other severe complications requiring a change in the standard anticoagulation strategy; Need for balloon angioplasty, permanent stent placement, or planned initiation of antiplatelet or anticoagulation therapy within 24 hours after the procedure; More than 3 thrombectomy passes or puncture-to-recanalization time \\>90 minutes; Use of an intraoperative intravenous heparin bolus, excluding heparinized saline flush; Suspected embolic stroke due to infection or infectious endocarditis; Severe allergy to contrast agents or tirofiban.",{"count":79,"type":21},344,[24],"The goal of this clinical trial is to learn if immediate intra-arterial tirofiban after complete recanalization can improve recovery in adults with acute ischemic stroke caused by anterior circulation large-vessel occlusion. It will also learn about the safety of this treatment. The main questions it aims to answer are:\n\nDoes immediate intra-arterial tirofiban after complete recanalization increase the number of participants with good functional outcome at 90 days? Does this treatment increase the risk of symptomatic intracranial hemorrhage or other important bleeding events?\n\nResearchers will compare immediate intra-arterial tirofiban with no intra-arterial tirofiban after complete recanalization to see if tirofiban improves recovery and is safe.\n\nParticipants will:\n\nBe enrolled after mechanical thrombectomy achieves complete recanalization Be randomly assigned to receive intra-arterial tirofiban or no intra-arterial tirofiban Receive follow-up assessments during hospitalization and at 90 days",[59,83,30],"Large-vessel Occlusion","2026-04-17",{"date":86,"type":35},"2026-04-22",{"date":88,"type":21},"2026-04",{"date":90,"type":21},"2028-04",{"name":92,"class":93},"Shandong Provincial Hospital","OTHER_GOV",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":102,"enrollmentInfo":103,"targetDuration":105,"studyType":106,"phases":4,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":43},"100380222","circulating-non-coding-rna-in-acute-ischemic-stroke-with-endovascular-treatment-evtrna-100380222","NCT04230785","Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)","Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke With Endovascular Treatment (EVTRNA)","EVTRNA","Inclusion Criteria:\n\n* Aged 18 years or older\n* Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan\n* Within 24 hours of symptom onset and treat with endovascular therapy\n* Good performance status\n* Signed an approved informed consents\n\nExclusion Criteria:\n\n* a history of hemorrhagic infarction, chronic kidney\u002Fliver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases","90 Years",{"count":104,"type":21},300,"90 Days","OBSERVATIONAL","EVTRNA is to analyze the differentiated expression pattern of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA) by next-generation sequencing in acute ischemic stroke patients before and\u002For after endovascular treatment. The candidate circRNA\u002FlncRNA\u002FmiRNA will be verified as the biomarker and regulator for progression and prognosis of acute ischemic stroke with endovascular treatment. Further, the candidate non-coding RNA will be used to evaluate the effect of endovascular treatment on both peripheral and central immune after stroke.",[109,110,30],"Stroke, Acute","Stroke, Ischemic",[112,113,114,115,116],"acute ischemic stroke","noncoding RNA","endovascular treatment","clinical significance","outcome","2026-04-06",{"date":119,"type":35},"2026-04-09",{"date":121,"type":35},"2020-03-15",{"date":123,"type":21},"2026-12-01",{"name":125,"class":42},"Nanjing First Hospital, Nanjing Medical University",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":43},"100625541","phase-2-advancing-reperfusion-therapy-for-ischemic-stroke-safety-and-efficacy-of-anakinra-for-futile-reperfusion-following-endovascular-treatment-in-patients-with-acute-ischemic-stroke-100625541","NCT07423975","Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke","Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke (SAFE)","ARTS-SAFE","Inclusion Criteria:\n\n* Age between 18-80 years old (both inclusive);\n* Acute ischemic stroke symptom onset within 24 hours; including wake-up stroke and unwitnessed stroke, onset time refers to \"last-seen normal time\";\n* Pre-stroke modified Rankin scale (mRS) score ≤1;\n* Baseline National Institutes of Health Stroke Scale (NIHSS) 6-25 (both inclusive);\n* Internal carotid artery (ICA) or middle cerebral artery (MCA) M1\u002FM2 occlusions confirmed by CTA\u002FMRA and responsible for the signs and symptoms of acute ischemic stroke;\n* Successful recanalization (eTICI 2b50-3) after endovascular treatment;\n* Written informed consent from patients or their legally authorized representatives.\n\nExclusion Criteria:\n\n* Allergy to Anakinra;\n* NIHSS consciousness score 1a \\>2, or epileptic seizure, hemiplegia after seizures (Todd's palsy) or other neurological\u002Fmental illness such that the patient is not able to cooperate or unwilling to cooperate;\n* Unable to perform CTP or PWI;\n* Acute or past intracerebral hemorrhage (ICH) (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural\u002Fepidural hematoma) confirmed by CT or MRI;\n* Multiple arterial occlusion (e.g., bilateral MCA occlusion, MCA occlusion accompanied with basilar occlusion);\n* Glomerular filtration rate (GFR) \\\u003C30 mL\u002Fmin or serum creatinine level \\>2.5 mg\u002FdL;\n* Suspected septic embolism or infective endocarditis;\n* Neutropenia (ANC \\\u003C1.5 × 109\u002FL);\n* Known active or recurrent liver disease (including cirrhosis, hepatitis B and C; positive or indeterminate laboratory results), or alanine aminotransferase (ALT)\u002Faspartate aminotransferase (AST) levels \\>3 times the upper limit of normal (ULN) or total bilirubin \\>2 times ULN;\n* History of malignancy other than basal cell carcinoma of the skin;\n* History or evidence of active or latent tuberculosis infection, or presence of tuberculosis risk factors including but not limited to: close contact with active tuberculosis patients within the past 12 months;\n* Any terminal illness such that the patient would not be expected to survive more than 1 year;\n* Pregnant women, nursing mothers, or reluctance to use effective contraceptive measures during the period of trial;\n* Unlikely to adhere to the trial protocol or follow-up;\n* Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study;\n* Participation in other interventional clinical trials within the previous 3 months.","80 Years",{"count":136,"type":21},159,[138],"PHASE2","The investigators initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to explore the safety and efficacy of different dose of Anakinra compared to standard medical care for patients with acute ischemic stroke who have achieved successful recanalization after endovascular thrombectomy.",[141,30],"Stroke Acute",[112,114,143,144],"successful recanalization","Anakinra","2026-02-14",{"date":147,"type":35},"2026-02-20",{"date":149,"type":21},"2026-03-01",{"date":151,"type":21},"2026-12-31",{"name":41,"class":42},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":167,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":172,"leadSponsor":173,"locationsCount":43},"100622931","the-efficacy-and-safety-of-endovascular-treatment-for-acute-mild-basilar-artery-occlusion-100622931","NCT07390032","The Efficacy and Safety of Endovascular Treatment for Acute Mild Basilar Artery Occlusion","The Efficacy and Safety of Endovascular Treatment for Acute Mild Basilar Artery Occlusion: A Multicenter, Prospective, Open-Label, Endpoint-Blinded, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Age≥18\n2. Acute ischemic stroke in posterior circulation, the time from stroke onset (or finally found normal) to randomization was within 24 hours\n3. Acute basilar artery occlusion confirmed by CTA,MRA,or DSA\n4. NIHSS score≥2 points and\\\u003C10 points from the onset of the disease to before randomization\n5. Posterior circulation large core infarction:NCCT or DWI showed pc-ASPECTS≥6, or Pons-Midbrain Index (PMI)\\\u003C3\n6. No significant functional disability before stroke (mRS≤2 points)\n7. Each patient or their legal representative must provide written informed consent before enrolment\n\nExclusion Criteria:\n\n1. Any sign of intracranial hemorrhage (except microbleeds) on brain imaging prior to randomization\n2. Complete cerebellar infarct with significant mass effect, or bilateral thalamic infarction as evidenced by baseline neuroimaging\n3. Known or highly suspected chronic occlusion of basilar artery\n4. History of contraindication for contrast medium (except mild rash)\n5. CTA\u002FMRA\u002FDSA confirmed occlusion of anterior and posterior circulation\n6. Severe stenosis, arterial dissection, or excessive tortuosity of the extracranial or intracranial segments of the vertebral artery may result in the inability of interventional instruments to be successfully delivered or positioned\n7. Current pregnant or breast-feeding\n8. Refractory hypertension (defined as systolic blood pressure\\>185 mmHg or diastolic blood pressure\\>110 mmHg) that cannot be controlled by drug treatment\n9. Known hereditary or acquired bleeding tendency, lack of coagulation factors, or oral anticoagulants with INR\\>1.5\n10. Blood glucose\\\u003C2.8 or\\>22.2 mmol\u002FL; Platelet count\\\u003C100\\*109\u002FL, serum creatinine\\>2.0 g\u002FL (177 μ mol\u002FL), or glomerular filtration rate\\\u003C30 ml\u002F(min\\*1.73 m2)\n11. Enrolled in another drug or device trial or expected to participate in another drug or device treatment trial within the following 3 months\n12. Acute cerebral infarction occurred within 48 hours after cardio cerebral vascular intervention or major surgery (patients over 48 hours can be included in the group)\n13. Patients whose life expectancy is less than 1 year (such as patients with malignant tumor, advanced cardiopulmonary disease, etc.)\n14. Central nervous system vasculitis has been diagnosed or clinically suspected\n15. Known to have dementia or psychiatric disease unable to complete neurological assessment and follow-up\n16. It is known that patients with dementia or mental illness cannot complete neurological function assessment and follow-up\n17. Any other condition (in the opinion of the site investigator) that inappropriate to participate this study",{"count":161,"type":21},230,[54],"This study assesses the efficacy and safety of endovascular treatment for acute mild basilar artery occlusion within a multicenter, prospective, open-label, endpoint-blinded, randomized controlled clinical trial.",[165,166,30],"Acute Mild Basilar Artery Occlusion","Basilar Artery Occlusion",[59,165,166,30],"2026-01-28",{"date":170,"type":35},"2026-02-05",{"date":149,"type":21},{"date":67,"type":21},{"name":69,"class":42},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":106,"phases":4,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":43},"100428626","the-safety-and-efficiency-of-endovascular-treatment-of-acute-or-subacute-thromboembolic-occlusions-of-lower-extremity-100428626","NCT04861506","The Safety and Efficiency of Endovascular Treatment of Acute or Subacute Thromboembolic Occlusions of Lower Extremity.","Physician-initiated, Prospective, Multi-center, Observational Study: The Safety and Efficiency Result of Endovascular Treatment of Acute or Subacute Thromboembolic Occlusions of Lower Extremity.","Inclusion criteria\n\n1. Patients aged 18 years or older.\n2. Diagnosis of acute or subacute limb ischemia classified as Rutherford classification stage I to IIb.\n3. Rutherford classification ranging from 3 to 5.\n4. Successful guidewire passage through the lesion of the femoropopliteal artery lesion, followed by further endovascular treatment. There are no restrictions will be implemented on the methods used for guidewire passage through the target lesion. The presence of thrombus must be confirmed via angiography and\u002For DSA and must be associated with occlusions of the lower extremity or ISR.\n5. Mechanical thrombectomy device (MTD) and\u002For pharmacomechanical thrombectomy (PMT) and\u002For percutaneous aspiration thrombectomy(PAT) and\u002For CDT (catheter-directed thrombolysis) performed for thrombus removal.\n6. The lower extremity artery must have a healthy runoff of at least 10 cm above the ankle with at least one healthy dorsalis pedis artery, medial plantar artery, or lateral plantar artery connecting to the digital artery below the ankle.\n7. Informed consent signed by patients.\n\nExclusion criteria\n\n1. Acute or subacute limb ischemia patients with Rutherford classification stage III.\n2. Patients diagnosed with thromboangiitis obliterans.\n3. Patients requring open surgery or hybrid operation after contrast radiography.\n4. Patients with a history of stroke, cerebral hemorrhage, gastrointestinal bleeding, myocardial infarction, or similar conditions in the past 3 months.\n5. Patients with known allergies to heparin, low molecular weight heparin, or contrast agents.\n6. Patients at high risk for bleeding.\n7. Pregnant or lactating women.\n8. Patients with other conditions that may complicate study participation or significantly reduce life expectancy (\\\u003C 2 years), such as tumors, severe liver disease, and cardiac insufficiency.\n9. Patients enrolled in other clinical studies within the past 3 months.\n10. Patients unwilling or refusing to sign the informed consent form.\n\n    \\-",{"count":182,"type":21},400,"Based on the development of new tools, including drug coated balloon, paclitaxel eluting stent, interwoven stents, debulking tools, More and more acute or subacute thromboembolic occlusions of lower extremity included stage IIb were treated with endovascular procedures. Most guidelines suggests only stage I and stage IIa lesions are suitable for endovascular treatments. Therefore, a well-designed real-world study that track the safety and clinical relevant outcomes, are required to determine the optimal therapies for patients with acute or subacute thromboembolic occlusions of lower extremity.",[185,186,30,187,188],"Thromboembolic Disease","Lower Extremity Problem","Safety Issues","Efficacy, Self","2025-09-12",{"date":191,"type":35},"2025-09-15",{"date":193,"type":35},"2021-04-01",{"date":195,"type":21},"2025-12-31",{"name":197,"class":42},"First People's Hospital of Hangzhou",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":213,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":43},"100603067","the-effect-of-transcutaneous-vagal-nerve-stimulation-tvns-on-cerebral-vasospasm-secondary-to-aneurysmal-subarachnoid-hemorrhage-100603067","NCT07131696","The Effect of Transcutaneous Vagal Nerve Stimulation (tVNS) on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid Hemorrhage","Inclusion Criteria:\n\n* Provision of signed and dated informed consent\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or Female\n* 18-65 years of age\n* Diagnosed with Fisher grade 3 or 4 aneurysmal subarachnoid hemorrhage\n* Ability to undergo endovascular treatment of aneurysmal subarachnoid hemorrhage\n* For females of reproductive potential: negative pregnancy test at time of treatment.\n* Plan to undergo standard of care treatment and follow-up\n\nExclusion Criteria:\n\n* Medically unfit to undergo endovascular treatment (e.g., Hunt Hess grade 5)\n* Does not provide consent\n* Posterior circulation aneurysmal subarachnoid hemorrhage\n* Initial aneurysm treatment after post bleed day 1","65 Years",{"count":206,"type":21},10,[54],"The significance of developing a safe and effective therapy for aneurysmal subarachnoid hemorrhage (aSAH) patients suffering cerebral vasospasm (CVS) cannot be overstated. Vasospasm - a clamping down of normal arteries in the days following rupture - remains incredibly challenging to treat.1,2 Current drugs and minimally invasive surgical therapies are helpful, yet woefully insufficient. Symptomatic cerebral vasospasm afflicts about 30% of aneurysmal subarachnoid hemorrhage patients and nearly half will go on to suffer a stroke, despite aggressive medical care.1-3 The autonomic nervous system is a balance between sympathetic (fight or flight) and parasympathetic (rest and digest) influence with sympathetic overactivity and inflammation shown to play an important role in the development and severity of cerebral vasospasm.4,5,17-20 Prior studies of autonomic nervous system neuromodulation highlight its promise as a promising potential avenue to improve morbidity and mortality from CVS in aSAH.6-15 Despite progress, continued high levels of CVS morbidity and mortality stress the urgent need for exploration of neuromodulation therapy.\n\nIn this proposal, the study team will modulate the autonomic nervous system function in aSAH patients using transcutaneous vagal nerve stimulation (tVNS). tVNS involves placement of a stimulation electrode on the external ear to non-invasively stimulate a branch of the vagal nerve and increase parasympathetic influence. This device has FDA approval for epilepsy and cluster headache.\n\nThe study hypothesis is that neuromodulation of the autonomic nervous system with tVNS (increasing parasympathetic influence) reduces sympathetic overactivity and inflammation in aSAH resulting in decreased morbidity of CVS.",[210,211,212,30],"Aneurysmal Subarachnoid Hemorrhage","Vasospasm, Cerebral","Transcutaneous Vagal Nerve Stimulation (tVNS)",[214,215,216],"CVS","aSAH","tVNS","2025-08-12",{"date":219,"type":35},"2025-08-20",{"date":221,"type":21},"2026-09",{"date":223,"type":21},"2028-09",{"name":225,"class":42},"Marshall Holland",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":233,"targetDuration":4,"studyType":22,"phases":235,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":43},"100575473","middle-meningeal-artery-embolization-for-patients-with-chronic-subdural-hematoma-100575473","NCT06772740","Middle Meningeal Artery Embolization for Patients With Chronic Subdural Hematoma","Randomized Clinical Trial of Middle Meningeal Artery Embolization for Patients With Chronic Subdural Hematoma (COMPLEMENT Study)","Inclusion Criteria:\n\n1. Age \\>=18\n2. pre-mRS 0-3\n3. Hematoma thickness \\>=10mm\n4. Having at least one risk factor Risk factor: Age \\>=75, Antithrombotic therapy, DM, Bilateral hematoma, Markwalder grading score \\>3, Preoperative volume \\>=130ml, Preoperative midline shift \\>=8mm, CT appearance (Homogeneous, laminar or separated)\n\nExclusion Criteria:\n\n1. Cr \\>=1.8\n2. Plt \\\u003C50,000, PT-INR \\>2\n3. Life expectancy \\\u003C6 months",{"count":234,"type":21},600,[54],"COMPLEMENT study (ChrOnic subdural hematoMa Patients suppLemented with Embolization of Middle mENingeal artery Trial) is a prospective, open label, blinded endpoint (PROBE), Japanese, two-arm, randomized, controlled, post-market study to assess the efficacy and safety of middle meningeal artery embolization for chronic subdural hematoma.",[30,238],"Chronic Subdural Hematoma","2025-05-26",{"date":241,"type":35},"2025-05-28",{"date":243,"type":35},"2024-12-23",{"date":245,"type":21},"2029-03-31",{"name":247,"class":42},"Kazutaka Uchida",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":43},"100576694","phase-3-glucagon-like-peptide-1-receptor-agonist-in-acute-large-vessel-occlusion-stroke-after-endovascular-treatment-100576694","NCT06788626","Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment","GALLOP2","Inclusion Criteria:\n\n1. LVO stroke at terminal ICA, M1 or dominant M2 with an LKW-to-randomization ≤24 hours\n2. Age ≥ 18 years old\n3. National Institute of Health Stroke Scale ≥ 6 at the time of brain imaging\n4. Acute LVO stroke due to thromboembolism or intracranial stenosis\n5. Patients who received computer tomographic or magnetic resonance angiography\n6. ASPECTS ≥ 6 for patients with LKW-to-randomization ≤6 hours\n7. Salvageable ischemic penumbra demonstrated by CT perfusion or MRI for patients with LKW-to-randomization between 6 and 24 hours\n8. Informed consent obtained from patient or acceptable patient surrogate.\n\nExclusion Criteria:\n\n1. Use of intravenous thrombolytic therapy (alteplase or tenecteplase)\n2. Pre-stroke mRS \\> 2 for patients \\\u003C80 years and \\> 1 for patients ≥ 80 years old\n3. Intracranial hemorrhage or brain tumour on initial imaging (except small meningiomas)\n4. Simultaneous occlusion of bilateral anterior circulation, or both anterior and posterior circulation\n5. Unstable hemodynamics on presentation that require resuscitation\n6. Systolic blood pressure \\>185mmHg or diastolic blood pressure \\>110mmHg that cannot be controlled by antihypertensive drugs\n7. Severe comorbid illness, e.g. terminal malignancy with life expectancy \\\u003C1 year\n8. Pregnant or lactating female\n9. Participation in another clinical trial\n10. Contraindications to GLP1-RA, including history of allergy to GLP-1RA, family or personal history of multiple endocrine neoplasia, medullary thyroid or pancreatic carcinoma, or proliferative diabetic retinopathy\n11. Blood glucose \\\u003C2.7 or \\> 22.2 mmol\u002FL; platelet count \\\u003C50x10\\^9 \u002FL; INR \\>1.7\n12. Patients with known estimated glomerular filtration rate of \\\u003C30ml\u002Fmin\u002F1.73m2 or creatinine \\>3mg\u002FdL (265.2µmol\u002FL); chronic liver disease with Child's Pugh score C or above; or recurrent unexplained hypoglycemia.\n13. Suspected or confirmed vasculitis of the central nervous system\n14. Unable to complete 90-day follow-up assessment",{"count":256,"type":21},390,[24],"The goal of this clinical trial is to learn if semaglutide works to treat acute ischemic stroke (AIS). It will also learn about the safety of semaglutide in AIS. The main question it aims to answer is: Does semaglutide improve the 90-days functional outcome in participants with acute large vessel occlusion who receive the endovascular treatment (EVT)? Researchers will compare semaglutide injection to non-injection to see if semaglutide works to improve the functional outcome in participants with EVT.\n\nParticipants will:\n\n* Receive 0.5mg semaglutide injection before (Day 0) and 1 week (Day 7) after EVT , or EVT alone.\n* Have additional blood test before and after EVT.\n* Receive neurological assessment before EVT, Day 1, Day 3, Day 5-7 after EVT or on hospital discharge (whichever earlier), Day 90±14 after EVT. Audio or video of the assessment may be recorded if possible.\n* Receive brain CT + CT angiogram + CT perfusion and MRI after EVT, where the CT scan may be repetitive.",[59,260,261,30],"Large Vessel Occlusion","Neuroprotective Drugs","2025-01-21",{"date":264,"type":35},"2025-01-23",{"date":266,"type":21},"2025-02",{"date":268,"type":21},"2028-02",{"name":270,"class":42},"Wei Hu",{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":281,"conditions":282,"keywords":283,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":43},"100539251","phase-3-combination-of-hypothermia-and-thrombectomy-in-acute-stroke-100539251","NCT06301412","Combination of Hypothermia and Thrombectomy in Acute Stroke","Combination of Targeted Temperature Management and Thrombectomy After Acute Ischemic Stroke (COTTIS-2) - a Randomised Controlled Study","COTTIS-2","Inclusion Criteria:\n\n* Pre-stroke modified Rankin Scale (mRS) 0-2 \\[7-point scale rating from 0 (no symptoms) to 6 (dead)\\]\n* Acute ischemic stroke with NIHSS \\>5\n* Intracranial occlusion of the M1 or M2 segment of the middle cerebral artery (MCA) or internal carotid artery (ICA) or tandem occlusion on CT-angiography or MR-angiography with indication for endovascular treatment:\n* Time window 0-24h:\n\n  1. Last seen normal to groin puncture \\\u003C 6h: native CT or MRI-DWI with ASPECTS \\>5\n  2. Last seen normal to groin puncture 6-24h or unknown time window: significant mismatch imaging according to the eligibility criteria of the DEFUSE-3 trial\n\n     * Infarct core \\\u003C70ml (DWI oder CBF\\\u003C30%)\n     * Penumbra \\> 15ml (Tmax \\>6sec)\n     * Ratio penumbra\u002Fcore \\>1.8\n* with or without iv thrombolysis with rtPA\n\nExclusion Criteria:\n\n* Patients with an intranasal obstruction that prevents complete insertion of the nasal cannula should not be treated with the RhinoChill system.\n* Known severe hemorrhagic diathesis (International Normalized Ratio (INR) \\>3.0, partial thromboplastin time (PTT) \\> 70s, platelet count \\\u003C 50.000\u002Fμl)\n* Brain trauma or neurovascular surgery\u002Fintervention \\\u003C3 months\n* Severe infection\n* Pregnant women or women of childbearing potential (women of childbearing potential with negative pregnancy test may be included)\n* Known cerebral vasculitis\n* Proof of bleeding in cerebral CT or MRI (cerebral microbleeds in MRI \\[hypertensive or in the context of cerebral amyloid angiopathy\\] is permitted).\n* Known life expectancy \\\u003C 6 months",{"count":182,"type":21},[24],"The goal of this clinical trial is to test the combination of hypothermia and endovascular treatment in acute stroke patients with large vessel occlusion.\n\nThe main question it aims to answer is: does an additional cooling to 35°C result in a benefit on clinical outcome ? Participants receive immediate cooling using a noninvasive transnasal cooling technique (RhonoChill) and are maintained at 35°C for 6 hours after reopening of the vessel using surface cooling, and then slowly rewarmed.\n\nResearchers will compare the intervention group (hypothermia and endovascular treatment and best medical treatment including iv thrombolysis) and control group (only endovascular treatment and best medical treatment including iv thrombolysis) to see if additional hypothermia leads to a better outcome after 3 months without relevant complications.",[27,260,30],[284,285],"hypothermia","neuroprotection","2025-01-02",{"date":288,"type":35},"2025-01-06",{"date":290,"type":35},"2024-07-07",{"date":292,"type":21},"2026-06-18",{"name":294,"class":42},"University of Freiburg",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":134,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":309,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":320},"100551795","endovascular-treatment-for-mild-ischemic-stroke-due-to-acute-large-vessel-occlusion-in-the-anterior-circulation-100551795","NCT06464731","Endovascular Treatment for Mild Ischemic Stroke Due to Acute Large Vessel Occlusion in the Anterior Circulation","Endovascular Treatment for Mild Ischemic Stroke Due to Acute Large Vessel Occlusion in the Anterior Circulation: A Multicenter Prospective Registry","Mild-MT","Inclusion Criteria:\n\n1. Age 18-80 years old;\n2. Symptoms onset or last known well to randomization is within 24 hours.\n3. Clinical diagnosis of acute ischemic stroke due to anterior circulation intracranial large vessel occlusion (LVO) (including intracranial internal carotid artery \\[ICA\\], middle cerebral artery \\[MCA\\] M1 segment, MCA M2 segment, with or without ipsilateral extracranial ICA occlusion) confirmed on Computerized tomography angiography (CTA) or Magnetic resonance imaging angiography (MRA) ;\n4. Baseline NIHSS score \\\u003C6 before randomization (including cases with NIHSS ≥6 at onset but improves before randomization);\n5. ASPECTS score ≥6 based on Non-contrast CT (NCCT) before randomization;\n\nExclusion Criteria:\n\n1. Premorbid Rankin Scale (mRS) score ≥ 1;\n2. Known allergy to iodine, heparin, anaesthesia, or other definite contraindication to receiving endovascular treatment (EVT) procedure;\n3. Patient has severe or fatal co-morbidities that could interfere with outcome assessments and follow-up (such as malignant tumor, severe heart failure, or renal failure, or life expectancy less than 6 months);\n4. Poorly controlled hypertension (systolic blood pressure \\>220 mmHg or diastolic blood pressure \\>120 mmHg);\n5. Baseline blood glucose \\\u003C50mg\u002FdL (2.78 mmol\u002FL) or \\>400mg\u002FdL (22.20 mmol\u002FL);\n6. Known bleeding tendencies, including but not limited to platelet count \\\u003C100×109\u002FL; received heparin treatment within 48 hours with an activated partial thromboplastin time (APTT) ≥35s; recent oral anticoagulant therapy with international normalized ratio (INR) \\>3; Note: Patients without a history of coagulation abnormalities or without suspicion of coagulation abnormalities do not need to wait for laboratory test results before enrollment;\n7. Seizures at stroke onset or during the course, hard to accurately judge the baseline NIHSS score;\n8. Female who is known to be pregnant, lactation, or tested positive for pregnancy at time of admission;\n9. Currently participating in another investigational drug study or medical device treatments that may interfere with the results of this study;\n10. Evidence of intracranial hemorrhage on CT\u002FMRI, including cerebral parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, and subdural\u002Fextradural hemorrhage;\n11. Significant midline displacement, hernia of brain, or ventricular mass effect with midline displacement confirmed on CT\u002FMRI;\n12. Anticipated impossibility to complete endovascular treatment, such as vascular tortuosity, severe vascular wall calcification, etc.;\n13. Aortic dissection;\n14. Multiple intracranial large vessel occlusions confirmed by CTA or MRA, unable to clearly identify the symptomatic vessel, such as bilateral MCA occlusions or occlusions involving both the MCA and basilar artery;\n15. Suspected or confirmed occluded artery is non-acute occlusion.",{"count":304,"type":21},200,[54],"Explore the effectiveness and safety of emergency endovascular treatment in patients with mild ischemic stroke due to acute large vessel occlusion in the anterior circulation, identified through perfusion imaging.",[30,308],"Mild Stroke",[114,310],"mild stroke","2024-06-12",{"date":313,"type":35},"2024-06-18",{"date":315,"type":35},"2017-01-01",{"date":317,"type":21},"2024-12-30",{"name":319,"class":42},"Wen-huo Chen",9,{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":328,"enrollmentInfo":329,"targetDuration":105,"studyType":106,"phases":4,"briefSummary":331,"conditions":332,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":43},"100471907","application-of-standardized-green-channel-treatment-system-for-ischemic-stroke-in-xi-an-100471907","NCT05424978","Application of Standardized Green Channel Treatment System for Ischemic Stroke in Xi 'an","Asgctsis","Inclusion Criteria:\n\n* 18 years old;\n* Consistent with the diagnosis of acute ischemic stroke;\n* 24 hours from onset to enrollment;\n* Informed consent\n\nExclusion Criteria:\n\n* Patients who refuse to receive intravenous thrombolysis or intravascular intervention (including intravascular mechanical thrombolysis and arterial thrombolysis);\n* Stroke patients caused by brain tumor, brain trauma and blood diseases;\n* Those with a history of stroke and sequelae affecting the outcome assessment, namely, mRS 2 points before the onset of this stroke;\n* Combined with claudication osteoarthritis rheumatoid arthritis gout arthritis and other limb dysfunction and affect the neurological function examination;\n* Patients with severe hepatic and renal insufficiency (Note: Hepatic insufficiency refers to ALT or AST values greater than 2 times the upper normal limit; Renal insufficiency refers to blood creatinine value greater than 2 times the normal upper limit);\n* Suffering from other serious life-threatening diseases with an expected survival time of less than 3 months;\n* Other diseases that limit neurological function evaluation or affect patient follow-up;\n* A woman planning to be pregnant or breastfeeding;\n* Currently participating in other clinical trials;\n* Refuse to participate in the registration of investigators","100 Years",{"count":330,"type":21},3600,"Objective: To observe the practical application of the standardized green channel treatment system for stroke in Xi 'an in the real world. Methods: Clinical data and information of patients with acute ischemic stroke who received standardized green channel treatment for stroke were collected, and a multicenter observational clinical study was carried out in the real world to evaluate the prognosis, mortality, incidence of asymptomatic and symptomatic cerebral hemorrhage, incidence of pneumonia, and recurrence rate of stroke after 90 days.",[59,333,30],"Thrombolysis","2024-01-24",{"date":336,"type":35},"2024-01-26",{"date":338,"type":35},"2022-06-01",{"date":340,"type":21},"2028-07-31",{"name":342,"class":93},"Xi'an No.3 Hospital"]